

Infektiologie und Tropenmedizin – Was gibt es Neues 2007?

Dr. med. M. Löbermann,
Prof. Dr. med. Emil C. Reisinger

aus BDI aktuell 10/2007

- 1** Anonymus . **Newer approaches to HIV prevention.** Lancet 2007; 369: 615
- 2** Bailey RC, Moses S, Parker CB. et al. **Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.** Lancet 2007; 369: 643-656
- 3** Blumenthal R, Dimitrov DS. **Targeting the Sticky Fingers of HIV-1.** Cell 2007; 129: 243-345
- 4** Brooks JT, Ochieng JB, Kumar L. et al. **Surveillance for bacterial diarrhea and antimicrobial resistance in rural western Kenya, 1997 - 2003.** Clin Infect Dis 2006; 43: 393-401)
- 5** CDC . **Pertussis-United States, 2001 - 2003.** MMWR Morb Mortal Wkly Rep 2005; 54: 1283-1286
- 6** Chen AY, Zervos MJ, Vazquez JA. **Dalbavancin: a novel antimicrobial.** Int J Clin Pract 2007; 61: 853-863
- 7** Chretien JP, Anyamba A, Bedno SA. et al. **Drought-associated chikungunya emergence along coastal East Africa.** Am J Trop Med Hyg 2007; 76: 405-407
- 8** Clotet B, Bellos N, Molina JM. et al. **Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.** Lancet 2007; 369: 1169-1178
- 9** Dewan PK, Grinsdale J, Kawamura LM. **Low sensitivity of a whole-blood interferon-gamma release assay for detection of active tuberculosis.** Clin Infect Dis 2007; 44: 69-73
- 10** Friedman LN, Nash ER, Bryant J. et al. **High rate of negative results of tuberculin and QuantiFERON tests among individuals with a history of positive skin test results.** Infect Control Hosp Epidemiol 2006; 27: 436-441
- 11** Gray RH, Kigozi G. et al. **Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial.** Lancet 2007; 369: 657-666
- 12** Greenwald JL, Burstein GR, Pincus J, Branson B. **A rapid review of rapid HIV antibody tests.** Curr Infect Dis Rep 2006; 8: 125-131
- 13** Grinsztejn B, Nguyen BY. et al. **Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.** Lancet 2007; 369: 1261-1269
- 14** Hampton T. **Marburg vaccine shows promise: offers postexposure protection in monkeys.** Jama 2006; 295: 2346
- 15** Harper DM. et al. **Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18l.** Lancet 2006; 367: 1247-1255
- 16** Hasenoehrl A, Galic T. et al. **In Vitro Activity and In Vivo Efficacy of Icofungipen (PLD-118), a Novel Oral Antifungal Agent, against the Pathogenic Yeast Candida albicans.** Antimicrob Agents Chemother 2006; 50: 3011-3018
- 17** Hasin T, Davidovitch N, Cohen R. et al. **Postexposure treatment with doxycycline for the prevention of tick-borne relapsing fever.** N Engl J Med 2006; 355: 148-155
- 18** Hicks CB, Cahn P, Cooper DA. et al. **Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.** Lancet 2006; 368: 466-475

- 19** Hill DR, Ford L, Lalloo DG. **Oral cholera vaccines: use in clinical practice.** Lancet Infect Dis 2006; 6: 361-373
- 20** Hoffmann H, Loytved G, Bodmer T. **Interferon- γ Release-Assays in der Tuberkulosedagnostik.** Internist (Berl) 2007; 48: 497-506
- 21** Högenauer C, Hammer FH, Krejs GJ, Reisinger EC. **Mechanisms and Management of Antibiotic-Associated Diarrhea.** Clin Infect Dis 1998; 27: 702-710
- 22** Högenauer C, Langner C, Beubler E. et al. **Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis.** N Engl J Med 2006; 355: 2418-2426
- 23** Hornberger J, Robertus K. **Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.** Ann Intern Med 2006; 145: 317-325
- 24** Kabir S. **Cholera vaccines.** Lancet Infect Dis 2007; 7: 176-178
- 25** Klug SJ, Hukelmann M, Hollwitz B. et al. **Prevalence of human papillomavirus types in women screened by cytology in Germany.** J Med Virol 2007; 79: 616-525
- 26** Kobashi Y, Obase Y. et al. **Clinical reevaluation of the QuantiFERON TB-2G test as a diagnostic method for differentiating active tuberculosis from nontuberculous mycobacteriosis.** Clin Infect Dis 2006; 43: 1540-1546
- 27** Krause R, Schwab E, Bachhiesl D, Wenisch C, Krejs GJ, Reisinger EC. **Role of Candida in Antibiotic-Associated Diarrhea.** J Infect Dis 2001; 184: 1065-1069
- 28** MacArthur RD. **Darunavir: promising initial results.** Lancet 2007; 369: 1143-1144
- 29** Menzies D, Pai M, Comstock G. **Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research.** Ann Intern Med 2007; 146: 340-345
- 30** Munch J, Standker L, Adermann K. et al. **Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion Peptide.** Cell 2007; 129: 263-275
- 31** Nataro JP, Mai V, Johnson J. et al. **Diarrheagenic Escherichia coli infection in Baltimore, Maryland, and New Haven, Connecticut.** Clin Infect Dis 2006; 43: 402-407
- 32** Oxman MN, Levin MJ, Johnson GR. et al. **A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.** N Engl J Med 2005; 352: 2271-2284
- 33** Pai M, Menzies D. **Interferon-gamma release assays: what is their role in the diagnosis of active tuberculosis?.** Clin Infect Dis 2007; 44: 74-77
- 34** Raad I, Hanna H, Jiang Y. et al. **Comparative Activities of Daptomycin, Linezolid, and Tigecycline against Catheter-Related Methicillin-Resistant Staphylococcus Bacteremic Isolates Embedded in Biofilm.** Antimicrob Agents Chemother 2007; 51: 1656-1660
- 35** SurvStat. 2007. (Accessed 30.04.2007, 2007, at <http://www3.rki.de/SurvStat>.)
- 36** Reisinger EC, Burchard GD. **Neues in der Infektiologie und Tropenmedizin.** Dtsch Med Wochenschr 2006; 131: 1474-1478
- 37** RKI. **Zum Welttuberkulosestag 2007. Tuberkulose irgendwo heißt Tuberkulose überall!.** Epidemiol Bul 2007; 11: 87-93
- 38** Rothberg MB, Virapongse A, Smith KJ. **Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.** Clin Infect Dis 2007; 44: 1280-1288
- 39** Schmiedeskamp MR, Kockler DR. **Human papillomavirus vaccines.** Ann Pharmacother 2006; 40: 1344-1352
- 40** Seedat J, Zick G, Klare I, Konstabel C, Weiler N, Sahly H. **Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection.** Antimicrob Agents Chemother 2006; 50: 4217-4219

- 41 Sidley P. South Africa acts to curb spread of lethal strain of TB. *Bmj* 2006; 333: 825
- 42 Steiner TS, Samie A, Guerrant RL. Infectious diarrhea: new pathogens and new challenges in developed and developing areas. *Clin Infect Dis* 2006; 43: 408-410
- 43 STIKO. Empfehlung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut zur Pertussis-Schutzimpfung. *Epidemiol Bull* 2006; 3: 21-23
- 44 STIKO. Neuerungen in den aktuellen Empfehlungen der Ständigen Impfkommission (STIKO) am RKI vom Juli 2006. *Epidemiol Bull* 2006; 32: 271-276
- 45 STIKO. Impfung gegen humane Papillomaviren (HPV) für Mädchen von 12 bis 17 Jahren - Empfehlung und Begründung. *Epidemiol Bull* 2007; 12: 97-103
- 46 Taylor DN, Bourgeois AL. et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. *Am J Trop Med Hyg* 2006; 74: 1060-1066
- 47 Teo JW, Thayalan P, Beer D. et al. Peptide deformylase inhibitors as potent antimycobacterial agents. *Antimicrob Agents Chemother* 2006; 50: 3665-3673
- 48 Tornesello ML. et al. Prevalence of human papillomavirus genotypes and their variants in high risk West Africa women immigrants in South Italy. *Infect Agent Cancer* 2007; 2: 1
- 49 Treanor JJ, Schiff GM. et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. *Jama* 2007; 297: 1577-1582
- 50 Tribble DR, Sanders JW, Pang LW. et al. Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. *Clin Infect Dis* 2007; 44: 338-346
- 51 UNAIDS. Report on the global AIDS epidemic 2006. Geneva: UNAIDS 2006
- 52 WHO. Guidelines for the treatment of severe malaria. (Accessed 2007 - 05 - 11, 2007, at www.who.int/malaria/docs/TreatmentGuidelines2006.pdf) 2006
- 53 Xu QA, Yu F, Fan MW. et al. Immunogenicity and persistence of a targeted anti-caries DNA vaccine. *J Dent Res* 2006; 85: 91591-91598
- 54 Xu QA, Yu F, Fan MW. et al. Protective efficacy of a targeted anti-caries DNA plasmid against cariogenic bacteria infections. *Vaccine* 2007; 25: 1191-1195
- 55 Stryjewski ME, Chu VH, O'Riordan WD. et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 Study. *Antimicrob Agents Chemother* 2006; 50(3): 862-867
- 56 Kohli M, Ferko N, Martin A. et al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. *Br J Cancer* 2007; 96(1): 143-150
- 57 Dondorp A, Nosten F, Stepniewska K. et al. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. *Lancet* 2005; 366(9487): 717-725